Daitto Vanilla my new favourite drink.
Daitto Vanilla my new favourite drink.
"Invest in your health now, or pay for it later"

Suggested For You
小薇和Alan祝大家新年快乐🫶🏻
小薇和Alan祝大家新年快乐🫶🏻

Selamat berpuasa semua 😀
Selamat berpuasa semua 😀
恭喜Wellous💚 又拿奖了🤩
恭喜Wellous💚 又拿奖了🤩
Very proud of Wellous 😍
👍👍👍
👍👍👍

WellFam Update!
WellFam Update!
We’re #1 in Online Marketing!
Wellous has been ranked Malaysia’s #1 in Online Marketing by BusinessLogy, reaffirming our growth and innovation! 🎉 Plus, our manufacturing arm, MOH Pharmaceutical Technologies, secured #18 out of 182 in a top industry report!
Big thanks to our team, partners, and you, WellFam for making this happen!
🎉 BIG NEWS! 🎉
🎉 BIG NEWS! 🎉
Our TIGER MILK KING has been awarded the “Top Functional Food for Lung Wellness of the Year” by The Knights Award Season 3! 🏆 This prestigious recognition celebrates the exceptional quality of our products and our commitment to supporting your lung health and overall well-being. Thank you for being part of our journey and trusting Tigrox to prioritize your health. Your support fuels our dedication to excellence! 💖 Here’s to more milestones and healthier tomorrows together. 💚✨

Hi i'm new here. Greetings to all ☺️
Hi i'm new here. Greetings to all ☺️
Hello
Hello
After took Zenso I lost 6kg. Its been 8 months now I still with my target weight. Now I just took Frusso just to maintained my weight and for my constipation. So happy & no regret trying Zenso. Happy Chinese New Year everyone🧧🧨😊
After took Zenso I lost 6kg. Its been 8 months now I still with my target weight. Now I just took Frusso just to maintained my weight and for my constipation. So happy & no regret trying Zenso. Happy Chinese New Year everyone🧧🧨😊
你知道吗?🤔 将近 40% 马来西亚成年人患有非酒精性脂肪肝(NAFLD),这也是马来西亚最常见的肝脏疾病。
你知道吗?🤔 将近 40% 马来西亚成年人患有非酒精性脂肪肝(NAFLD),这也是马来西亚最常见的肝脏疾病。
我们最新一期的时事简报将带你深入探讨肝脏健康!本期的资讯内容涵盖了一系列常见的肝脏疾病,探索了预防病毒性肝炎和脂肪肝的方法,以及我们本期的重点产品 - LIVETAL 和 HOMEGA,为你的肝脏健康助力加持!还有,也别错过了试试我们这期的数字排毒挑战,让自己暂时“退出”数字世界,全面地身心放松!🧡✨
点击下方链接查看完整的时事简报,了解更多关于保持肝脏健康的知识吧!🥰
👉 https://cdn.wellous.com/membership/article/newsletter/2024/2024-q2-cn.pdf
